Hemoglobinopathies Market Thumbnail Image

2022

Hemoglobinopathies Market

Hemoglobinopathies Market Size, Share, Competitive Landscape and Trend Analysis Report, by Type, by Therapy, by Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2022-2031

LS : Healthcare

Select an option
Author's: Swapna Singh | Roshan Deshmukh
Publish Date:

Get Sample to Email

Hemoglobinopathies Market Research, 2031

The global hemoglobinopathies market was valued at $4.2 billion in 2021, and is projected to reach $7 billion by 2031, growing at a CAGR of 5.2% from 2022 to 2031.

The hemoglobinopathies are group of inherited disorders carries from parents to offspring. Hemoglobinopathies occurs due to mutations in the gene of hemoglobin molecule. The two main types of hemoglobinopathies are hemoglobin (Hb) variant occurs due to hemoglobin gene mutation and thalassemia caused due to insufficient hemoglobin production. The various hemoglobinopathies, such as thalassemia, sickle cell disease, hemoglobin variant, and beta thalassemia give rise to various health problems. Furthermore, the health problems associated with the disease are blurred vision, heart problems, slowed growth, gallstones, spleen enlargement, and stroke. Increase in disease prevalence is the main factor for market growth.

Hemoglobinopathies Market

The development and research for the treatment is increased, which lead to boost the market growth during the hemoglobinopathies market forecast period. Moreover, the current treatment available are monoclonal antibody medication, ACE inhibitors, hydroxyurea, and others. Other therapies include, gene therapy and iron chelation therapy. Increase in disease count, new methods adopted for screening and novel research and development activities is expected to propel the hemoglobinopathies market share growth during the forecast period.

According to the World Health Organization (WHO), hemoglobinopathies affects 330,00 newborn infants every year as it is inherited from the parents. The high prevalence is observed in the low- and middle-income countries. . According to WHO, high prevalence of common rare blood related diseases is observed in Europe. The various pharmaceutical leaders of the industry involved in novel treatment development, which is expected to accelerate the market growth.

Furthermore, the high-cost treatment and lack of awareness sustain the growth of market at some point. During the COVID-19 period, the need for hemoglobinopathies decreased significantly. The focus is moved to the virus‐™s spread, leading to market expansion. For instance, therapies such as bone marrow transplantation, gene therapy, and blood transfusion require hospitalization of the patient. In addition, the diagnosis methods used for the hemoglobinopathies are total blood count and special hemoglobin tests. In various hospitals, screening of newborn for inherited diseases is mandatory. According to WHO, approximately 5% of adult, globally are carriers hemoglobin related disorders, from which 2.9% are affected by thalassemia and 2.1% carry sickle cell disease.

The growth of hemoglobinopathies market size is driven by increased research & development of new medicines and therapies and increased disease prevalence, which contribute positively to market revenue growth during the forecast period. Moreover, increase in the numbers of patients seeking hemoglobinopathies treatments in developing countries such as Africa and India is responsible to drive the hemoglobinopathies market growth.

Impact of COVID-19

Coronavirus severe acute respiration syndrome (SARS-CoV-2) is an infectious disease caused by the novel coronavirus (COVID-19), which originated in the Wuhan district in China in the late 2019, and since has spread to 212 countries. The virus was initially referred to as ‐novel coronavirus 2019‐ (2019-nCoV) by the WHO, However, on February 11, 2020, it was given the official name of SARS-CoV-2 by the International Committee on Taxonomy of Viruses. WHO declared COVID-19 as pandemic on March 11, 2020, and by September 1, 2020, over 28.1 million people have been infected globally with over 909,000 deaths. COVID-19 symptoms include fever, cough, and shortness of breath.

Nearly all industries have been impacted by the global public health COVID-19 pandemic. As coronavirus crises sweep the globe and force healthcare organizations to devote the majority of their funds to fight COVID-19, the outbreak of COVID-19 has resulted in a significant decline in demand for the hemoglobinopathies market across several sectors, particularly the health and pharmaceutical sectors. The main cause of the interruptions experienced by patients getting treatment for hemoglobinopathies in hospitals was the risk of infection. The treatments for thalassemia and sickle cell disease requires hospitalization for blood transfusion and bone marrow transplantation, hence the hemoglobinopathies market size declined in this period. As a result, the COVID-19 outbreak is expected to slow down the global market growth for treatments of hemoglobinopathies, which will have a negative effect on the market's value in 2022 and beyond.

The hemoglobinopathies market is segmented into Type, Therapy and Distribution Channel.

The hemoglobinopathies market is segmented on the basis of type, therapy, distribution channel, and region. By type, it is segmented into thalassemia, sickle cell disease, and others. By therapy, the market is bifurcated into monoclonal antibody medication, ACE inhibitors, hydroxyurea, and others. By distribution channel, the market is fragmented into hospital pharmacy, online providers, and drug stores and retail pharmacy.

Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Hemoglobinopathies Market
By Type
Your browser does not support the canvas element.

Thalassemia segment held the major share of 5.7% throughout the forecast period.

Type of Disease Segment Review

By type, the thalassemia segment was the highest revenue contributor to the market. In the coming days, the market is expected to accelerate as the thalassemia prevalence is increasing in newborn as well in adults. The growth of this segment is increased due to a strong approved medicine and other therapies in pipeline. Other diseases from this segment, such as sickle cell disease also contribute to the market growth.

Hemoglobinopathies Market
By Therapy
Your browser does not support the canvas element.

Hydroxyurea segment Enterprises segment was the highest revenue contributor during the forecast period.

Therapy Segment Review

By therapy, the monoclonal antibody medication segment was the highest revenue contributor to the market, due to sufficient medicines available for the treatment. Thalassemia shows the potent recovery by the monoclonal antibody medication. The market growth is driven by newly developed and approved therapies by the industry leaders.

Hemoglobinopathies Market
By Distribution Channel
Your browser does not support the canvas element.

Online Providers segment Enterprises segment was the highest revenue contributor during the forecast period.

Distribution Channel Segment Review

By distribution channel, the drug stores and retail pharmacy segment is the highest revenue contributor to the market. The drug stores and retail pharmacy segment is the most reliable segment as it ensures the treatment given to the patient, on the basis of prescription from the physician with accurate dose, route of administration and in time.

Hemoglobinopathies Market
By Region
2031
North America 
Europe
Asia-Pacific
LAMEA

North America was holding a dominant position in 2021 and would continue to maintain the lead over the analysis period.

Region Segment Review

Region-wise, North America was the highest revenue contributor, owing to increased hemoglobinopathies count, increase in patients seeking hemoglobinopthies treatments, and increasing R&D activities boost the market growth. In addition, the growth of this hemoglobinopathies industry is driving by availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment.

Major key players that operate in the global hemoglobinopathies market are Abbott Laboratories, Alnylam Pharmaceuticals, Biogen Idec, Bluebird, Inc., Bristol Myers Squibb Company, Canthera Discovery Ltd., Danaher, Emmaus Life Sciences, Inc., F. Hoffman-La Roche Ag, Gamida Cell Ltd., Global Blood Therapeutics, Merck & Co, Novartis AG, Pfizer, Inc, Prolong Pharmaceuticals, LLC, Sangamo Therapeutics, and Sanofi.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hemoglobinopathies market analysis from 2021 to 2031 to identify the prevailing hemoglobinopathies market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hemoglobinopathies market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hemoglobinopathies market trends, key players, market segments, application areas, and market growth strategies.

 

Hemoglobinopathies Market Report Highlights

Aspects Details
icon_1
Market Size By 2031

USD 7 billion

icon_2
Growth Rate

CAGR of 5.2%

icon_3
Forecast period

2021 - 2031

icon_4
Report Pages

315

icon_5
By Type
  • Thalassemia
  • Sickle Cell Disease
  • Others
icon_6
By Therapy
  • Monoclonal Antibody Medication
  • ACE inhibitors
  • Hydroxyurea
  • Others
icon_7
By Distribution Channel
  • Hospital Pharmacy
  • Online Providers
  • Drug Stores and Retail Pharmacy
icon_8
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
icon_9
Key Market Players

Sangamo Therapeutics, Inc., Sanofi S.A., Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Pfizer, Global Blood Therapeutics, Inc., Biogen Inc., CANTHERA DISCOVERY LTD., Merck & Co. Inc., Novartis AG, Prolong Pharmaceuticals LLC., Danaher Corporation

Analyst Review

Hemoglobinopathies are caused by mutation in the gene of DNA of hemoglobin molecule. Structural abnormalities in the hemoglobin molecule generate defective red blood cells, which is a root cause of sickle cell diseases. Furthermore, the presence of hemoglobin-related diseases is higher in Asia and Africa region. According to World Health Organization (WHO), 7.0% of the world’s population are affected by the hemoglobinopathies. World Health Organization (WHO) also estimated that 30,000-40,000 newborn babies carry the severe hemoglobinopathies from their parents as genetic disorder.

The structural abnormalities and the deficient production of hemoglobin molecule differentiate the various types of hemoglobinopathies, such as hemoglobin variants and thalassemia respectively. To treat the underlying causes of the disorders, various treatment methods have been employed in the past, including monoclonal antibody medications, angiotensin-converting enzyme for the treatment of renal dysfunctioning caused due to sickle cell diseases, hydroxyurea, gene therapy and iron chelation therapy.

Furthermore, thalassemia is the major disease among other hemoglobinopathies, hence R&D leaders of the industry are focused on finding new, cost effective, and potent treatments for hemoglobinopathies. The revenue growth of the market is driven by the development of new gene therapies, screening of newly born infants, and increase in prevalence in developing and low-cost countries.

Increase in screening of hemoglobinopathies, developing new techniques for diagnosis of diseases, newly developing therapies, and rise in knowledge about thalassemia and sickle cell anemia diseases, are expected to boost the hemoglobinopathies market during the forecast period.

Author Name(s) : Swapna Singh | Roshan Deshmukh
Frequently Asked Questions?

The upcoming trends of Hemoglobinopathies Market includes development and research for the treatment is increased, which lead to boost the market growth during the forecast period.

The leading application of Hemoglobinopathies Market are thalassemia and sickle cell disease treatment.

North America is the largest regional market for Hemoglobinopathies.

Hemoglobinopathies market is expected to reach $7,011.44 million by 2031, with a CAGR of 5.2% from 2022 to 2031.

Major key players that operate in the global hemoglobinopathies market are Abbott Laboratories, Alnylam Pharmaceuticals, Biogen Idec, Bluebird, Inc., Bristol Myers Squibb Company, Canthera Discovery Ltd., Danaher, Emmaus Life Sciences, Inc., F. Hoffman-La Roche Ag, Gamida Cell Ltd., Global Blood Therapeutics, Merck & Co, Novartis AG, Pfizer, Inc, Prolong Pharmaceuticals, LLC, Sangamo Therapeutics, and Sanofi.

The forecast period for Hemoglobinopathies market is 2022 to 2031.

The base year is 2021 in Hemoglobinopathies market.

Loading Table Of Content...

Loading Research Methodology...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Hemoglobinopathies Market

Global Opportunity Analysis and Industry Forecast, 2022-2031